Barclays Maintains Overweight on Arcus Biosciences, Raises Price Target to $60
Barclays analyst Peter Lawson maintains Arcus Biosciences (NYSE:RCUS) with a Overweight and raises the price target from $48 to $60.
54 Biggest Movers From Yesterday
Gainers
Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the treatment of hypoplastic left heart syndrome.
44 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Longeveron Inc. (NASDAQ: LGVN) jumped 157% to $7.51. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the treatment of hypoplastic left heart syndrome.
SVB Leerink Maintains Outperform on Arcus Biosciences, Raises Price Target to $100
SVB Leerink analyst Geoffrey Porges maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $68 to $100.
Gilead Exercises Options To Three Arcus Biosciences Clinical-stage Programs And Adds Research Collaboration; Arcus To Receive Option Payments Totaling $725M
-- Gilead Exercises Options to Arcus's Anti-TIGIT Program (Domvanalimab and AB308), Etrumadenant (A2a/A2b Adenosine Receptor Antagonist) and Quemliclustat (Small Molecule CD73 Inhibitor) --
-- Arcus to Receive
Recap: Arcus Biosciences Q3 Earnings
Arcus Biosciences (NYSE:RCUS) reported its Q3 earnings results on Monday, November 8, 2021 at 04:10 PM.
Here's what investors need to know about the announcement.
Arcus Biosciences Q3 EPS $(1.11) Misses $(1.08) Estimate, Sales $9.46M Beat $9.40M Estimate
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(1.08) by 2.78 percent. This is a 3800 percent decrease over earnings of $0.03 per share from